Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Izeltabart Tapatansine · IMGC-936

Antibody-drug conjugate · Cytotoxic, directed at ADAM9

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Izeltabart Tapatansine?

Izeltabart tapatansine is an antibody-drug conjugate in which a humanized anti-ADAM9 monoclonal antibody is linked to the maytansinoid DM21, a microtubule-disrupting payload. After binding ADAM9 on tumor cells and being internalized, the payload is released and disrupts microtubule dynamics. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IMGC-936
Drug type
Antibody-drug conjugate
Targets
ADAM9, tubulin (secondary target)
Mechanism
Cytotoxic, directed at ADAM9
Pathways
microtubule assembly/disassembly, cell division inhibition, cytokine and growth factor shedding, cell migration
Therapy area
Oncology
In trials of
MGNX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
LL3U59WXR1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04622774 Phase 1/2 Advanced Solid Tumor Completed MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on ADAM9

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.